FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an isolated antibody or its antigen-binding fragment, which with specificity bind a ligand of canine programmed cell death 1 PD-L1. Also disclosed is a pharmaceutical composition containing said antibody. Disclosed is a method for increasing the activity of an immune cell using said antibody.
EFFECT: invention enables to effectively increase the activity of the immune cell.
14 cl, 2 dwg, 13 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PD-L1 ANTIBODIES BINDING DOG PD-L1 | 2015 |
|
RU2722562C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BINDING MOLECULES, BINDING PD-L1 AND LAG-3 | 2017 |
|
RU2784388C2 |
| MOLECULES BINDING WITH CD38 AND PD-L1 | 2017 |
|
RU2764201C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
